1. Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer
- Author
-
Herrero, Cristina, de la Fuente, A., Casas-Arozamena, Carlos, Sebastian, V., Prieto, M., Arruebo, M., Abalo, Alicia, Colás Ortega, Eva, Moreno-Bueno, G., Gil-Moreno, Antonio, Vilar, A., Cueva, Juan, Abal Posada, Miguel, Muinelo-Romay, L., Universitat Autònoma de Barcelona, Universidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas, Instituto de Salud Carlos III, European Commission, Asociación Española Contra el Cáncer, and UAM. Departamento de Bioquímica
- Subjects
0301 basic medicine ,Cancer Research ,L1 ,Response to therapy ,Medicina ,Extracellular vesicles ,Article ,03 medical and health sciences ,0302 clinical medicine ,Endometrial cancer ,ANXA2 ,medicine ,Liquid biopsy ,EVs ,ExoGAG ,business.industry ,Cancer ,medicine.disease ,Technical performance ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,business ,Annexin A2 - Abstract
© 2019 by the authors., Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient´s outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-efficient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly efficient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses., This research was funded by Instituto de Salud Carlos III, grant PI17/01919, co-financed by the European Regional Development Fund (FEDER), and by Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Grupos Clínicos Coordinados 2018. Carolina Herrero is supported by a predoctoral i-PFIS fellowship from Instituto de Salud Carlos III (IFI17/00047); Laura Muinelo is supported by Asociación Española Contra el Cáncer (AECC).
- Published
- 2019